Go Pro
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
$109.51
-3.7%		$100.17
$22.76
▼
$117.88
$6.22B1.22765,581 shs735,467 shs
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$70.52
-4.3%		$77.73
$48.27
▼
$90.87
$6.15B0.561.23 million shs802,507 shs
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$64.46
-2.3%		$57.85
$17.05
▼
$66.24
$6.22B1.121.74 million shs1.07 million shs
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
$36.95
+3.7%		$10.50
$0.29
▼
$3.72
$1.57B3.931.22 million shs2.23 million shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
-1.59%+1.15%+12.57%+26.85%+400.88%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
+1.43%+1.42%-5.56%+5.56%+48.56%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
+3.22%+6.11%+18.91%+47.43%+274.13%
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
0.00%0.00%0.00%0.00%+205.12%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
$109.51
-3.7%		$100.17
$22.76
▼
$117.88
$6.22B1.22765,581 shs735,467 shs
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$70.52
-4.3%		$77.73
$48.27
▼
$90.87
$6.15B0.561.23 million shs802,507 shs
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$64.46
-2.3%		$57.85
$17.05
▼
$66.24
$6.22B1.121.74 million shs1.07 million shs
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
$36.95
+3.7%		$10.50
$0.29
▼
$3.72
$1.57B3.931.22 million shs2.23 million shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
-1.59%+1.15%+12.57%+26.85%+400.88%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
+1.43%+1.42%-5.56%+5.56%+48.56%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
+3.22%+6.11%+18.91%+47.43%+274.13%
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
0.00%0.00%0.00%0.00%+205.12%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
2.93
Moderate Buy$124.2713.48% Upside
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
2.64
Moderate Buy$98.5539.74% Upside
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2.69
Moderate Buy$61.67-4.33% Downside
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest UMRX, TVTX, DNTH, and PTCT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/17/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D+) ➝ Sell (D)
8/17/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
8/14/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$120.00 ➝ $122.00
8/13/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$106.00 ➝ $109.00
8/10/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$78.00
8/6/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$61.00 ➝ $75.00
8/6/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$62.00 ➝ $70.00
8/6/2026
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$110.00 ➝ $128.00
8/6/2026
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$130.00 ➝ $158.00
8/6/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/5/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 8/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
$2.04M2,934.76N/AN/A$21.44 per share5.11
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$1.73B3.40$8.41 per share8.39($1.98) per share-35.62
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$490.73M12.38$0.35 per share182.14$0.26 per share247.92
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
$22.50M69.74N/AN/A$1.04 per share35.53
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
-$162.34M-$4.15N/AN/AN/A-10,096.95%-22.53%-21.55%11/4/2026 (Estimated)
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$682.64M-$0.58N/A33.112.27-3.80%-362.45%-1.32%11/3/2026 (Estimated)
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$25.55M-$0.46N/A24.51N/A-7.35%-55.15%-6.88%10/29/2026 (Estimated)
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
-$31.83M-$1.04N/AN/AN/A-96.84%-87.78%-52.14%N/A

Latest UMRX, TVTX, DNTH, and PTCT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2026Q2 2026
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
-$0.8463-$0.90-$0.0537-$0.90$0.30 million$0.76 million
8/4/2026Q2 2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$0.1347-$0.10+$0.0347-$0.37$157.27 million$169.58 million
7/30/2026Q2 2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$0.2363$0.92+$0.6837$0.92$298.63 million$360.52 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
N/AN/AN/AN/AN/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/AN/AN/AN/AN/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/AN/AN/AN/AN/A
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
N/A
26.10
26.10
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
3.39
3.28
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
24.58
4.05
3.99
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
0.18
2.90
2.90

Institutional Ownership

CompanyInstitutional Ownership
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
47.53%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/A
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
26.39%

Insider Ownership

CompanyInsider Ownership
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
3.02%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
5.30%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
4.44%
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
31.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
8054.67 million53.02 millionOptionable
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
1,41083.46 million79.04 millionOptionable
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
46094.26 million90.08 millionOptionable
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
7242.47 millionN/ANot Optionable

Recent News About These Companies

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
August 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/cogent-biosciences-reports-recent-business-highlights-and-second-quarter-2026-financial-results-1036435465
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 ...
May 30, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/cogent-biosciences-announces-detailed-clinical-data-from-peak-phase-3-trial-with-bezuclastinib-in-combination-with-sunitinib-in-gastrointestinal-stromal-tumors-gist-at-2026-american-society-of-1036209656
Cogent Bio granted FDA priority review for lead asset in tumor indication
May 28, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4597892-cogent-granted-fda-priority-review-for-lead-asset
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO ...
April 21, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/cogent-biosciences-announces-oral-presentation-of-positive-phase-3-peak-trial-in-gastrointestinal-stromal-tumors-gist-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting-1036042508
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)
April 1, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/cogent-biosciences-announces-submission-of-new-drug-application-for-bezuclastinib-in-gastrointestinal-stromal-tumors-gist-1035985261
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
March 16, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/cogent-biosciences-announces-fda-acceptance-of-new-drug-application-for-bezuclastinib-in-patients-with-nonadvanced-systemic-mastocytosis-nonadvsm-1035932701
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough
February 17, 2026  |  fool.comhttps://www.fool.com/coverage/filings/2026/02/17/cogent-biosciences-stock-up-346-as-fund-builds-usd29-million-stake-after-november-phase-3-breakthrough/
Cogent Biosciences submits NDA for bezuclastinib in NONADVSM
December 30, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/cogent-biosciences-submits-nda-for-bezuclastinib-in-nonadvsm/ar-AA1Tisr9
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis
December 30, 2025  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2025/12/30/10310068.htm
Cogent Biosciences: Time For A Pause
December 15, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4853525-cogent-biosciences-time-for-a-pause
Cogent Biosciences price target raised to $48 from $45 at Jefferies
December 8, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/cogent-biosciences-price-target-raised-to-48-from-45-at-jefferies/ar-AA1RXhi2
Cogent Biosciences jumps after strong late-stage results in advanced systemic mastocytosis
December 8, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/cogent-biosciences-jumps-after-strong-late-stage-results-in-advanced-systemic-mastocytosis/ar-AA1RWwKu
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
December 8, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/cogent-biosciences-announces-positive-top-line-results-of-apex-trial-of-bezuclastinib-in-patients-with-advanced-systemic-mastocytosis-advsm-1035625401
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American ...
December 6, 2025  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2025/12/06/10301319.htm
HC Wainwright & Co. Maintains Cogent Biosciences (COGT) Buy Recommendation
November 14, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/hc-wainwright-co-maintains-cogent-biosciences-cogt-buy-recommendation/ar-AA1QpPe9
Cogent Biosciences price target raised to $50 from $21 at H.C. Wainwright
November 13, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/cogent-biosciences-price-target-raised-to-50-from-21-at-h-c-wainwright/ar-AA1QnC30
Cogent Biosciences’ phase 3 PEAK trial marks an advance in the treatment of gastrointestinal stromal tumors.
November 13, 2025  |  managedhealthcareexecutive.comM
Cogent Biosciences’ phase 3 PEAK trial marks an advance in the treatment of gastrointestinal stromal tumors.
November 13, 2025  |  managedhealthcareexecutive.comM
Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes ...
November 11, 2025  |  caledonianrecord.comC
Cogent Hits ‘Unprecedented’ Efficacy in Rare Stomach Cancer, Clearing Path to FDA
November 11, 2025  |  biospace.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Dianthus Therapeutics stock logo

Dianthus Therapeutics NASDAQ:DNTH

$109.51 -4.19 (-3.69%)
Closing price 04:00 PM Eastern
Extended Trading
$109.54 +0.03 (+0.03%)
As of 06:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

PTC Therapeutics stock logo

PTC Therapeutics NASDAQ:PTCT

$70.52 -3.15 (-4.28%)
As of 04:00 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Travere Therapeutics stock logo

Travere Therapeutics NASDAQ:TVTX

$64.46 -1.50 (-2.27%)
Closing price 04:00 PM Eastern
Extended Trading
$64.46 0.00 (0.00%)
As of 05:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Cogent Biosciences stock logo

Cogent Biosciences NASDAQ:UMRX

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas